These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27166257)

  • 41. Episodic Src activation in uveal melanoma revealed by kinase activity profiling.
    Maat W; el Filali M; Dirks-Mulder A; Luyten GP; Gruis NA; Desjardins L; Boender P; Jager MJ; van der Velden PA
    Br J Cancer; 2009 Jul; 101(2):312-9. PubMed ID: 19568237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
    Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
    Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis.
    Isaacson AL; Sompallae RR; Guseva NV; Bellizzi AM; Bossler AD; Ma D
    Am J Clin Pathol; 2022 Aug; 158(2):177-186. PubMed ID: 35212356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
    Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL
    Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
    Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors.
    Zhang GM; Huang SS; Ye LX; Liu XL; Shi WH; Ren ZL; Zhou RH; Zhang JJ; Pan JX; Liu SW; Yu L; Li YL
    Pharmacol Res; 2022 Oct; 184():106464. PubMed ID: 36162600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.
    Johansson PA; Brooks K; Newell F; Palmer JM; Wilmott JS; Pritchard AL; Broit N; Wood S; Carlino MS; Leonard C; Koufariotis LT; Nathan V; Beasley AB; Howlie M; Dawson R; Rizos H; Schmidt CW; Long GV; Hamilton H; Kiilgaard JF; Isaacs T; Gray ES; Rolfe OJ; Park JJ; Stark A; Mann GJ; Scolyer RA; Pearson JV; van Baren N; Waddell N; Wadt KW; McGrath LA; Warrier SK; Glasson W; Hayward NK
    Nat Commun; 2020 May; 11(1):2408. PubMed ID: 32415113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
    Ambrosini G; Khanin R; Carvajal RD; Schwartz GK
    Mol Cancer Ther; 2014 Aug; 13(8):2073-80. PubMed ID: 24899684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.
    Van Raamsdonk CD; Bezrookove V; Green G; Bauer J; Gaugler L; O'Brien JM; Simpson EM; Barsh GS; Bastian BC
    Nature; 2009 Jan; 457(7229):599-602. PubMed ID: 19078957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
    Royer-Bertrand B; Torsello M; Rimoldi D; El Zaoui I; Cisarova K; Pescini-Gobert R; Raynaud F; Zografos L; Schalenbourg A; Speiser D; Nicolas M; Vallat L; Klein R; Leyvraz S; Ciriello G; Riggi N; Moulin AP; Rivolta C
    Am J Hum Genet; 2016 Nov; 99(5):1190-1198. PubMed ID: 27745836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
    Gaffal E
    J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Uveal melanoma modeling in mice and zebrafish.
    van den Bosch QCC; de Klein A; Verdijk RM; Kiliç E; Brosens E;
    Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189055. PubMed ID: 38104908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
    Chua V; Han A; Bechtel N; Purwin TJ; Hunter E; Liao C; Harbour JW; Aplin AE
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):78-87. PubMed ID: 34347929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulator of G protein signaling 2 inhibits Gα
    Zhang Q; Haak AJ; Sjögren B
    J Biol Chem; 2022 Jun; 298(6):101955. PubMed ID: 35452684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repression of genes involved in melanocyte differentiation in uveal melanoma.
    Bergeron MA; Champagne S; Gaudreault M; Deschambeault A; Landreville S
    Mol Vis; 2012; 18():1813-22. PubMed ID: 22815634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exome sequencing reveals the likely involvement of SOX10 in uveal melanoma.
    Das D; Kaur I; Ali MJ; Biswas NK; Das S; Kumar S; Honavar SG; Maitra A; Chakrabarti S; Majumder PP
    Optom Vis Sci; 2014 Jul; 91(7):e185-92. PubMed ID: 24927141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
    Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.
    Lefevre G; Glotin AL; Calipel A; Mouriaux F; Tran T; Kherrouche Z; Maurage CA; Auclair C; Mascarelli F
    J Biol Chem; 2004 Jul; 279(30):31769-79. PubMed ID: 15145934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.